GlaxoSmithKline nabs 'breakthrough' label for Tafinlar in lung cancer

GlaxoSmithKline's ($GSK) new cancer drug Tafinlar won the FDA's "breakthrough therapy" designation for use in lung cancer patients. Already approved to treat melanoma, the drug snapped up a new approval last week for use in combination with another GSK melanoma treatment, Mekinist. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.